Retatrutide's Phase 1 and 2 Trials (2026): the 24.2% Drug

10 papers · each one re-checked on PubMed · last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

Tirzepatide added a second receptor to semaglutide's one and gained about six percentage points of weight loss. Retatrutide adds a third, glucagon, on the theory that burning more energy would push past the ceiling tirzepatide established. In phase 2 it did: 24.2% at 48 weeks, at the time the largest figure reported for an obesity drug. Every paper below is phase 2 or earlier. The first TRIUMPH phase 3 results were published in 2026 and are not on this list yet; in the phase 3 obesity trial, 12 mg produced a 25.0% weight loss at 80 weeks against 3.9% on placebo. Anything sold to you today under this name is still not the drug these trials studied.

Ranked papers

#1Retatrutide Phase 2 Obesity

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

Jastreboff AM, Kaplan LM, Frías JP, et al. · N Engl J Med · 2023

What it measured: Weight lost at 24 and 48 weeks across four doses

The trial the reputation rests on: 338 adults with obesity and no diabetes, on four doses or placebo for 48 weeks. At 12 mg the result was −24.2% against −2.1%. That is past tirzepatide's 20.9% ceiling and was, when published, the largest weight reduction any drug had produced in a randomized trial. Everyone on the top dose lost at least 5%, and 83% lost at least 15%. Still, 338 people over 48 weeks is a phase 2 trial, and it deserves phase 2 confidence.

PMID 37366315 ↗NCT04881760 ↗DOI 10.1056/NEJMoa2301972 ↗

#2Retatrutide Phase 2 T2D

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: phase 2 trial

Rosenstock J, Frias J, Jastreboff AM, et al. · Lancet · 2023

What it measured: Change in HbA1c at week 24

281 adults with type 2 diabetes across four doses, against dulaglutide and against placebo, over 36 weeks. The top dose cut A1C by 2.02 points where dulaglutide managed 1.41, and took off 16.9% of body weight. The design matters more than the numbers: it included an active comparator, so this is the first evidence that triple agonism beats a GLP-1 alone on both fronts rather than just looking impressive against placebo.

PMID 37385280 ↗NCT04867785 ↗DOI 10.1016/S0140-6736(23)01053-X ↗

#3Retatrutide MASLD Phase 2a

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Sanyal AJ, Kaplan LM, Frias JP, et al. · Nat Med · 2024

What it measured: How much liver fat disappeared by week 24

The liver substudy: 98 participants with at least 10% liver fat on imaging. The two top doses cleared roughly 82% of it against essentially no change on placebo at 24 weeks, and 79 to 86% of those participants ended below the 5% threshold that counts as a normal liver. This is measured by scan rather than biopsy, so it shows fat leaving the liver. Whether inflammation or scarring resolved is the question the phase 3 liver program has to answer.

PMID 38858523 ↗NCT04881760 ↗DOI 10.1038/s41591-024-03018-2 ↗

#4Retatrutide T2D body-comp substudy

Effects of retatrutide on body composition in people with type 2 diabetes: substudy of phase 2 trial

Coskun T, Wu Q, Schloot NC, et al. · Lancet Diabetes Endocrinol · 2025

What it measured: Fat, lean tissue and deep abdominal fat measured by body scan at 36 weeks

The substudy that addresses the obvious worry. Glucagon agonism drives energy expenditure, and there was a legitimate concern that a triple agonist would burn muscle along with fat. Of the 189 people in the substudy, 103 had DXA scans at both the start and week 36. Total fat mass fell by up to 26.1% (8 mg) against 4.5% on placebo, and lean mass made up a similar fraction of the loss as it does with other obesity treatments. That answers the muscle worry for now, although the result was published in 2025, after the phase 3 program had already started.

PMID 40609566 ↗NCT04867785 ↗DOI 10.1016/S2213-8587(25)00092-0 ↗

#5Retatrutide kidney post-hoc

The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes and/or Obesity

Heerspink HJL, Lu Z, Du Y, et al. · Kidney Int Rep · 2025

What it measured: Kidney function, and how much protein leaked into the urine

A post-hoc look at kidney measures in both phase 2 trials, reported trial by trial. Urine albumin fell 37% at 12 mg in type 2 diabetes and 28% and 32% at 8 and 12 mg in obesity. Kidney function (eGFR) did not change against placebo in diabetes and rose in obesity, by 5.3 and 8.5 mL/min. Most participants started with normal urine albumin, so the absolute reduction was modest. A post-hoc analysis is the weakest design on this page; the dedicated kidney trials are the fair test of a hypothesis-generating result.

PMID 40630318 ↗DOI 10.1016/j.ekir.2025.03.049 ↗

#6TRANSCEND-CKD (design)

Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease

Heerspink HJL, van Raalte DH, Bjornstad P, et al. · Nephrol Dial Transplant · 2026

What it measured: Change in measured kidney filtration (iohexol clearance) at 24 weeks

This is a design paper, not a result. TRANSCEND-CKD is a phase 2b mechanistic trial: 146 adults with chronic kidney disease (eGFR 25 to 75) and overweight or obesity, 38% of them with type 2 diabetes, randomized to retatrutide or placebo. Its main measure is the change in measured kidney filtration at 24 weeks, alongside MRI of kidney blood flow and of the fat around the kidneys. It is meant to explain the mechanism behind a separate cardio-kidney outcomes trial, TRIUMPH-Outcomes, and knowing what a trial measures is useful when someone quotes you its result early.

PMID 41160422 ↗NCT05936151 ↗DOI 10.1093/ndt/gfaf230 ↗

#7Retatrutide molecular discovery

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: From discovery to clinical proof of concept

Coskun T, Urva S, Roell WC, et al. · Cell Metab · 2022

What it measured: How strongly the molecule hits each receptor, then its effects in animals and first humans

The founding chemistry paper, plus first-in-human work. Lilly engineered a single peptide that acts on all three receptors, with balanced glucagon and GLP-1 activity and stronger GIP activity. In obese mice it cut weight and improved blood sugar, with extra energy expenditure from the glucagon receptor on top of the appetite effect of the other two. A single-ascending-dose phase 1 study then showed tolerability similar to other incretins and a drug profile that supported once-weekly dosing. Everything downstream on this list depends on the design choices documented here.

PMID 35985340 ↗DOI 10.1016/j.cmet.2022.07.013 ↗

#8Retatrutide Phase 1b T2D

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with T2D: phase 1b trial

Urva S, Coskun T, Loh MT, et al. · Lancet · 2022

What it measured: Safety, side effects and drug levels across escalating doses over 12 weeks

The phase 1b dose-ranging study: 72 patients with type 2 diabetes over 12 weeks, testing escalating doses for safety and supporting the move to phase 2. By week 12 the top-dose group had lost about 9 kg more than placebo, and A1C fell by up to 1.6 points against placebo (in the 3/6 mg group). Gastrointestinal side effects were the most common, as across the class. Both phase 2 trials started within six months of this study finishing.

PMID 36354040 ↗NCT04143802 ↗DOI 10.1016/S0140-6736(22)02033-5 ↗

#9Retatrutide gastric emptying

The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying

Urva S, O'Farrell L, Du Y, et al. · Diabetes Obes Metab · 2023

What it measured: How fast the stomach empties, tracked using absorption of a test dose of acetaminophen

A short Lilly report showing that retatrutide delays gastric emptying, measured by how quickly a test dose of acetaminophen is absorbed. PubMed carries no abstract for it, so the size of the delay is not summarized here. The finding matters to anyone weighing sedation or surgery risk on these drugs.

PMID 37311727 ↗DOI 10.1111/dom.15167 ↗

#10Retatrutide T2D appetite/eating substudy

Appetite, eating attitudes, and eating behaviours during treatment with retatrutide: phase 2 T2D substudy

Kanu C, Boye KS, Poon JL, et al. · Diabetes Obes Metab · 2025

What it measured: Hunger, cravings and eating behavior, self-reported on validated scales

A patient-reported substudy of 275 adults using validated appetite and eating-behavior questionnaires. On 4 mg or more, appetite and hunger fell more than on placebo by week 24, and perceived hunger and disinhibition (the tendency to overeat) fell more at 8 and 12 mg. Differences against dulaglutide were less consistent. People whose hunger and disinhibition fell most also lost the most weight. These are self-reports, so read them as a plausible explanation for the weight loss, not proof of the mechanism.

PMID 40916752 ↗NCT04867785 ↗DOI 10.1111/dom.70097 ↗

About this list

Obesity medicine throws up the same handful of questions over and over, and we answer them with ranked lists anchored to the papers themselves. On 2026-10-30 every citation below was put back through PubMed. Where a trial has a registry entry, the card carries that link too, alongside the PubMed one.

Browse our full index of research lists or our long-form research articles.